AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

652.737

-3.511-0.53%

Number of Gainers:8

Number of Losers:19

Number of Flat:18

PE:- -

High:657.335

Open:653.530

Low:645.360

Close:656.248

Volume:41.38M

Turnover:137.02M

Market Cap:97.03B

Float Cap:93.79B

Loading ...

BRIEF-Australian Government Takeovers Panel Made Orders For Cosette

ACRES Commercial Realty to Issue $879.5 Million in Debt Notes

MT Newswires Live

Australian Govt Takeovers Panel - Made Orders Requiring Cosette to Agree to Any Conditions Reasonably Required by Treasurer

THOMSON REUTERS

ViewSonic Debuts New Gaming Monitor with QD-OLED Panel and Enhanced Anti-Burn-In Features

BRIEF-Dimerix Appoints Mike Tonroe As CFO

Mesoblast (ASX:MSB) Valuation Check After FDA Backs Rexlemestrocel L’s Pain And Opioid Reduction Data

Simply Wall St.

Imricor Medical Systems Names US Academic Health System as Third Site for Heart Procedure Trial

MT Newswires Live

Dimerix Appoints CFO

MT Newswires Live

Dimerix Ltd-Appointment of CFO/Company Secretary

THOMSON REUTERS

FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms

FiberPro Secures KRW4.89 Billion Inertial Measurement Unit Supply Contract; Shares Jump 18%

MT Newswires Live

BRIEF-Immuron Reports H1 Global Travelan Sales AUD$4.2 Mln

Immuron Limited Reports 5% Increase in Global H1 Sales

Immuron Reports Continued Sales Growth

THOMSON REUTERS

Neuren Pharmaceuticals Confirms Compliance With ASX Listing Rules; Shares Down 4%

MT Newswires Live

BRIEF-Polynovo Logs HY Group Sales Of A$68.2M

BRIEF-Orthocell Posts Quarterly Revenue Of A$3.2 Million

BUZZ-Australia's PolyNovo jumps on upbeat half-yearly sales

BRIEF-Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L

Mesoblast Advances Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain Following FDA Support

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":652.7373,"timestamp":1768971599951,"preClose":656.2484,"halted":0,"volume":41379521,"delay":0,"changeRate":-0.00535,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-3.511108,"latestTime":"01-21 16:00:00 AEDT","open":653.5296,"high":657.3345,"low":645.36017,"amount":137024207,"amplitude":0.018247,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1769036400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1768950000000,1768971600000]],"turnoverRate":0.001589,"increases":7,"decrements":22,"flats":15,"marketCap":97025622455.25,"floatMarketCap":93785409452.875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":657.3345,"amplitude":0.018247,"preClose":656.2484,"low":645.36017,"latestPrice":652.7373,"volume":41379521,"delay":0,"open":653.5296,"prevYearClose":644.3692,"prevWeekClose":653.635,"prevMonthClose":644.369,"prevQuarterClose":644.369,"fiveDayClose":647.259,"twentyDayClose":649.741,"sixtyDayClose":769.118,"secType":"PLATE","market":"AU","turnoverRate":0.001589,"marketCap":97025622455.25,"floatMarketCap":93785409452.875,"timestamp":1768971599951,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":8,"down":19,"flat":18},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605039571","title":"BRIEF-Australian Government Takeovers Panel Made Orders For Cosette","url":"https://stock-news.laohu8.com/highlight/detail?id=2605039571","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605039571?lang=en_us&edition=fundamental","pubTime":"2026-01-21 18:30","pubTimestamp":1768991420,"startTime":"0","endTime":"0","summary":"BRIEF-Australian Government Takeovers Panel Made Orders For CosetteJan 21 (Reuters) - AUSTRALIAN GOVERNMENT TAKEOVERS PANEL - MADE ORDERS REQUIRING COSETTE TO AGREE TO ANY CONDITIONS REASONABLY REQUIRED BY TREASURERFurther company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YL1KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2605987174","title":"ACRES Commercial Realty to Issue $879.5 Million in Debt Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2605987174","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605987174?lang=en_us&edition=fundamental","pubTime":"2026-01-21 16:36","pubTimestamp":1768984580,"startTime":"0","endTime":"0","summary":"ACRES Commercial Realty  said Tuesday that it will issue through a subsidiary $879.5 million in non-recourse, floating-rate notes at a weighted-average cost of the one-month term secured overnight financing rate plus 168 basis points.The transaction is expected to close by Feb. 12.The notes are collateralized by around $1 billion of floating-rate first mortgage loans originated by the company and $200 million in cash, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK4110","ACR.AU","BK7508","ACR"],"gpt_icon":0},{"id":"2605173871","title":"Australian Govt Takeovers Panel - Made Orders Requiring Cosette to Agree to Any Conditions Reasonably Required by Treasurer","url":"https://stock-news.laohu8.com/highlight/detail?id=2605173871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605173871?lang=en_us&edition=fundamental","pubTime":"2026-01-21 14:24","pubTimestamp":1768976697,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nFWN3YL1KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2605800122","title":"ViewSonic Debuts New Gaming Monitor with QD-OLED Panel and Enhanced Anti-Burn-In Features","url":"https://stock-news.laohu8.com/highlight/detail?id=2605800122","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605800122?lang=en_us&edition=fundamental","pubTime":"2026-01-21 11:46","pubTimestamp":1768967160,"startTime":"0","endTime":"0","summary":"SUBANG JAYA,Malaysia, Jan. 21, 2026 /PRNewswire/ -- ViewSonic Corp., a leading global provider of visual solutions, has introduced the XG2738-2K-OLED, a new 27-inch monitor in the ViewSonic Gaming lineup. Designed for both competitive and immersive gameplay, it combines a 2K QD-OLED panel with high-speed performance and the ViewSonic OLED Care anti-burn-in solution to deliver long-term panel reliability.The XG2738-2K-OLED features a 240Hz refresh rate and an ultra-fast 0.03ms GTG response time, ensuring smooth motion and precise clarity during fast-paced action. A dedicated 24.5-inch esports mode further optimizes visibility and contrast for competitive gaming environments.Get immersed in vibrant visuals with the 2KQHD resolution QD-OLED panel. Experience smooth gameplay with the 240Hz refresh rate and rapid up to 0.03  response time. Scale down from 27-inch to a laser-focused 24.5-inch esports setting built for competitive precision. Enjoy tear-free gaming with NVIDIA G-Sync compatibi","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2864984/Image_1_Key_Visual.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2864984/Image_1_Key_Visual.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/viewsonic-debuts-new-gaming-monitor-with-qd-oled-panel-and-enhanced-anti-burn-in-features-302666022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","OLED","BK4573","BK7508","BK4141","GTG.AU","BK4585","BK4518"],"gpt_icon":0},{"id":"2605125721","title":"BRIEF-Dimerix Appoints Mike Tonroe As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2605125721","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605125721?lang=en_us&edition=fundamental","pubTime":"2026-01-21 09:37","pubTimestamp":1768959451,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Appoints Mike Tonroe As CFOJan 21 (Reuters) - Dimerix Ltd DXB.AX:APPOINTMENT OF CFO/COMPANY SECRETARYAPPOINTS MIKE TONROE AS CFOFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUE8GHV2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","DXB.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2605608122","title":"Mesoblast (ASX:MSB) Valuation Check After FDA Backs Rexlemestrocel L’s Pain And Opioid Reduction Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2605608122","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605608122?lang=en_us&edition=fundamental","pubTime":"2026-01-21 08:47","pubTimestamp":1768956470,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) is back in focus after feedback from the U.S. FDA on its rexlemestrocel L cell therapy, which targets chronic discogenic low back pain and is directly linked to opioid use reduction.\nSee our latest analysis for Mesoblast.\nDespite the positive FDA feedback, Mesoblast’s recent share price momentum has been soft, with a 7 day share price return of a 7.0% decline and a 30 day share price return of a 12.7% decline, while the 3 year total shareholder return of 177.6% points to a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-after-fda-backs-rexlemestro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-after-fda-backs-rexlemestro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK7508","MSB","BK7067","MSB.AU","BK7501","BK4006"],"gpt_icon":0},{"id":"2605883128","title":"Imricor Medical Systems Names US Academic Health System as Third Site for Heart Procedure Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2605883128","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605883128?lang=en_us&edition=fundamental","pubTime":"2026-01-21 08:12","pubTimestamp":1768954351,"startTime":"0","endTime":"0","summary":"Imricor Medical Systems  said Virginia Commonwealth University Health in the US will serve as the third site in the company's Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter  clinical trial, according to a Wednesday filing with the Australian bourse.The trial investigates the safety and efficacy of radiofrequency ablation of ventricular tachycardia performed with the company's product Vision-MR Ablation Catheter 2.0, the company said in an August 2023 statement.The company expects to start final budgeting, installation, and training at the site in February and procedures in March, the filing said.Shares of the company fell 1% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","BK7503","IMR.AU","BK7508"],"gpt_icon":0},{"id":"2605114264","title":"Dimerix Appoints CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2605114264","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605114264?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:24","pubTimestamp":1768947849,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) appointed Mike Tonroe as chief financial officer, effective Jan. 29, according to a Wednesday filing with the Australian bourse.Tonroe brings over 30 years of experience, having most recently served as the CFO of Imugene (ASX:IMU), the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DXB.AU","IMU.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2605415141","title":"Dimerix Ltd-Appointment of CFO/Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2605415141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605415141?lang=en_us&edition=fundamental","pubTime":"2026-01-21 05:28","pubTimestamp":1768944510,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nTUE8GHV2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2605110440","title":"FACTBOX-Global drugmakers rush to boost US presence as tariff threat looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2605110440","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605110440?lang=en_us&edition=fundamental","pubTime":"2026-01-21 01:08","pubTimestamp":1768928883,"startTime":"0","endTime":"0","summary":"FACTBOX-Global drugmakers rush to boost US presence as tariff threat loomsAdds details on Roche, Abbvie and CSL. Global drugmakers are ramping up U.S. manufacturing and stockpiling inventory as the Trump administration considers","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL4N3YL1OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1035775433.USD","LU1880407132.USD","LU2112291526.USD","LU2361044949.HKD","LU1868836757.USD","BK4592","LU2168564149.EUR","LU2091194634.USD","LU2133065610.SGD","LU0889566641.SGD","LU1674673691.USD","LU0203345920.USD","LU1061106388.HKD","SG9999001176.USD","BK4534","LU1244550494.USD","LU0820561909.HKD","IE00B1BXHZ80.USD","SG9999003800.SGD","IE00B3PB1722.GBP","LU1941712264.USD","LU2471134879.HKD","IE00BJJMRY28.SGD","NVS","LU0289961442.SGD","LU1868837136.USD","LU2750360997.AUD","LU2324357040.USD","LU2168564495.EUR","LU0128525689.USD","BK4533","03165","LU1983299246.USD","LU1221951129.SGD","LU0170899867.USD","LU0889565080.SGD","LU0289739343.SGD","LU1084165304.USD","LU1880407215.USD","LU2264538146.SGD","LU0972486137.USD","LU0472753341.HKD","LU0708995401.HKD","LU0960981461.USD","LU1814569148.SGD","CSL.AU","IE00B775H168.HKD","IE0005OL40V9.USD","LU2471134796.USD","LU0912757837.SGD","LU1804176565.USD","LU0526926950.USD","LU0345770308.USD","LU2129689605.HKD","LU0306807586.USD","IE00BKPKM643.USD","LU0353189763.USD","LU0499090636.EUR","LU0323591593.USD","LU0963555726.SGD","IE00BJT1NW94.SGD","JNJ","LU0211328371.USD","LU0949170772.SGD","LU2746668974.SGD","LU0354030438.USD","LU0211331839.USD","SG9999015945.SGD","LU0310800965.SGD","LU0557290698.USD","SG9999014914.USD","LU0316494557.USD","LU1267930490.SGD","LU1019632923.USD","LU0266013472.USD","LU2471134523.USD","LU0511384066.AUD","LU1232071149.USD","IE0004445239.USD","LU1868837300.USD","LU0122379950.USD","LU0784385170.HKD","LU1153585028.USD","LU1585245621.USD","BK7511","LU2168564222.USD","LU0225284248.USD","ABBV","LU1551013342.USD","IE00B1XK9C88.USD","LU2089283258.USD","LU1548497426.USD","LU1551013425.SGD","LU1674673428.USD","LU0889565916.HKD","LU1119994496.HKD","LU0471298777.SGD","BK4007","IE0004445015.USD","LU1116320737.USD","LU0757432116.USD","LU0868494617.USD","LU0471298694.HKD","IE00BGHQF631.EUR","AMGN","IE00B19Z9P08.USD","AZN","BK4504","LU0011850046.USD","LU0203347892.USD","LU0070302665.USD","SG9999015986.USD","LU0320765489.SGD","SG9999015952.SGD","LU2552382215.SGD","LU1989772840.SGD","LU0225283273.USD","LU2114397693.USD","LU0225771236.USD","LU0096364046.USD","LU1366192091.USD","LU0029864427.USD","LU0130517989.USD","LU1035773651.USD","LU2211815571.USD","LU2125154778.USD","LU1244550221.USD","LU1914381329.SGD","LU0792757196.USD","LU2237443382.USD","PFE","LU2106854487.HKD","LU0784384876.USD","LU0827474353.SGD","LU0786609619.USD","LU0823434740.USD","LU2237443549.SGD","LU0920783379.SGD","LU0787776722.HKD","IE00BN29S564.USD","LU2293690082.USD","LU0964806797.USD","SG9999017495.SGD","LU0882574139.USD","BIIB","SGXZ99366536.SGD","LU1883839398.USD","SGXZ31699556.SGD","LU1064927863.SGD","LU2265009873.SGD","LU0477156953.USD","LU2602419157.SGD","IE00BK4W5M84.HKD","LU0256863902.USD","LU1496350171.SGD","IE00BBT3K403.USD","LU1934455277.USD","LU1868836914.USD","LU2505996509.AUD","LU2237443465.HKD","LU1066051498.USD","LU0198837287.USD","LU1917777945.USD","BK7501","LU1280957306.USD","LU0965508806.USD","LU0784383803.USD","LU1127390331.HKD","BK4588","LU2491050071.SGD","LU2471134952.CNY","SG9999002224.SGD","LU0672654240.SGD","LU2552382058.USD","IE00BVYPNV92.GBP","SG9999015341.SGD","LU1323610961.USD","LU2430703095.HKD","LU1116320901.HKD","IE00B4JS1V06.HKD","LU1941712348.USD","LU2108987350.USD","LU0795875086.SGD","LU1301847155.USD","BK4566","LU1839511570.USD","BK4583","LU2236285917.USD","LU0077335932.USD","LU0784385840.USD","LU1032466523.USD","SGXZ81514606.USD","LU1051770623.HKD","LU0920840948.USD","LU0969580561.USD","LU1069344957.HKD","LU0345770993.USD","LU0823434583.USD","LU2430703178.SGD","LU1506573853.SGD","LU0052756011.USD","LU0353189680.USD","GILD","LU1720051017.SGD","LU1778281490.HKD","SG9999014880.SGD","LU1718418525.SGD","LU0354030511.USD","SG9999014542.SGD","LU0496365809.HKD","LU0683600562.USD","LU0861579265.USD","LU1571399168.USD","LU1934455863.HKD","LU0124676726.USD","LU1496350502.SGD","IE000M9KFDE8.USD","LU2456880835.USD","LU0070217475.USD","LU1481600234.SGD","LU2462157665.USD","LU1003076772.USD","IE00BSNM7G36.USD","LU0208291251.USD","LU1894683348.USD","LU0965509101.SGD","LU2461242641.AUD","LU0320765992.SGD","LU2491050154.USD","LU2746668461.USD","LU0689472784.USD","LU0047473722.EUR","LU0949170426.SGD","LU1935042991.SGD","LU2087625088.SGD","IE00B2B36J28.USD","LU0047473722.SGD","LU1162221912.USD","LU1974910355.USD","IE00BJJMRX11.SGD","LU1170363599.USD","LU0106261372.USD","LU0640478417.SGD","LU0823399737.USD","IE00B3T34201.USD","LU0320765059.SGD","LU0211326755.USD","IE00B7KXQ091.USD","LU0640476718.USD","LU0545039389.USD","RHHBY","LU1093756168.USD","LU0128525929.USD","IE00BKVL7J92.USD","BK5011","LU0097036916.USD","LU1066053197.SGD","LU0171293334.USD","LU0345777147.USD","LU0158827948.USD","LU0321505868.SGD","IE00B19Z3B42.SGD","LU1720051108.HKD","SG9999002232.USD","IE00BFXG1179.USD","SG9999014898.SGD","IE00BKDWB100.SGD","IE00BVYPNW00.USD","IE00B894F039.SGD","LU0058720904.USD","LU0234572021.USD","BK4139","LU1261432733.SGD","IE0002141913.USD","LU2417539215.USD","LU1201861249.SGD","LU0310799852.SGD","SG9999001176.SGD","SG9999018865.SGD","LU2125154935.USD","IE00BJJMRZ35.SGD","SGXZ51526630.SGD","IE00BK4W5L77.USD","LU0109394709.USD","LU0385154629.USD","LU2468319806.SGD","SG9999014567.USD","BK4599","LU2505996681.GBP","SG9999013999.USD","LU2023251221.USD","LU2592432038.USD","IE00B7SZLL34.SGD","LU2293690249.USD","IE0034235303.USD","LU0321505439.SGD","LU0857590862.USD","LU0211326839.USD","LU0057025933.USD","LU1196500208.SGD","LU2491049909.HKD","LU0882574055.USD","LU1929549753.HKD","LU0265550359.USD","LU0234570918.USD","LU0965509283.SGD","IE00BDGV0183.EUR","SG9999014575.USD","LU1267930730.SGD","LU0985320562.USD","LU1894683264.USD","IE00BKPKM429.USD","LU1989771016.USD","LU1712237335.SGD","LU1023059063.AUD","LU2089984988.USD","LU0738911758.USD","LU2237443622.USD","IE00B19Z9Z06.USD","LU1093756325.SGD","LU1037948897.HKD","LU0238689110.USD","IE00BJLML261.HKD","LU1868836591.USD","BK7508","BK4568","LU0943347566.SGD","IE00BZ1G4Q59.USD","LU0289739699.SGD","BK4516","LU2023250504.SGD","LU0203202063.USD","LU2750360641.GBP","LU0997586432.USD","LU0456855351.SGD","LU2168564065.EUR","LU0094547139.USD","LU1104425308.USD","LU1153584641.USD","LU0306806265.USD","IE00BFSS8Q28.SGD","GB00BDT5M118.USD","LU2168563687.JPY","LU0109391861.USD","LU0708994859.HKD","04332","LU2129689431.USD","LU0310800379.SGD","SG9999015358.SGD","LU1430594728.SGD","LU1064131342.USD","BK4532","LU1019634622.SGD","BK4559","LU1059921491.USD","IE00BLSP4452.SGD","SNY","IE00BN8TJ469.HKD","IE0034235188.USD","LU1487256676.USD","LU2242652126.USD","LU0965509010.AUD","LU1015430645.USD","LU0648001328.SGD","SG9999014906.USD","LU0957799991.USD","LU2089284900.SGD","LU0980610538.SGD","SG9999014559.SGD","LU0203201768.USD","LU0820561818.USD","LU1291159041.SGD","LU0130102774.USD","LU2357305700.SGD","LU2430703251.USD","LU1003077747.HKD","LU2360106947.USD","LU0661504455.SGD","LU2347655156.SGD","SG9999015978.USD","LU1481599808.USD","LU0006306889.USD","SG9999011175.SGD","IE00BFSS7M15.SGD","LU0976567544.SGD","LU1934455194.USD","LU2360032135.SGD","LU0575583348.USD","LU2237438978.USD","LU0265550946.USD","LU0345769631.USD","LU1267930573.SGD","LU1623119135.USD","IE00B4R5TH58.HKD","LLY","IE0002270589.USD","IE00B42XCP33.USD","LU0417517546.SGD","LU0256863811.USD","LU1267930813.SGD","LU2539964713.USD","LU1989772923.USD","LU1057294990.SGD","LU2361044865.SGD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","LU1988902786.USD","LU2361045086.USD","BK4578","BK4581","LU0553294199.USD","LU0689626769.HKD","LU1074936037.SGD","LU2552382132.HKD","LU0061475181.USD","LU0345777659.USD","LU1699723380.USD","LU1244550577.SGD","LU2237443978.SGD","IE00BLSP4239.USD","LU1732799900.SGD","LU0466842654.USD","LU1032955483.USD","LU2237443895.HKD","IE0009355771.USD","LU1066051225.USD","LU2063271972.USD","LU0211327993.USD","LU1078025761.USD","LU2242646821.SGD","LU0795875169.SGD","LU1267930227.SGD","LU0114720955.EUR","LU0345769128.USD","LU2087621335.USD","BK4585","SG9999001440.SGD","BK4550","LU0320765646.SGD","SG9999018857.SGD","LU2279689827.SGD","LU0432979614.USD","LU0079474960.USD","BK7067","IE00BWXC8680.SGD","LU0098860793.USD","LU0985481810.HKD","IE00B19Z3581.USD","LU2023250843.SGD","LU0069063385.USD","LU1732800096.USD","LU1037948541.HKD","LU2129689514.USD","LU1221951046.USD","LU1069347547.HKD","MRK","LU0823416689.USD","LU1066051811.HKD"],"gpt_icon":1},{"id":"2604165686","title":"FiberPro Secures KRW4.89 Billion Inertial Measurement Unit Supply Contract; Shares Jump 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604165686","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604165686?lang=en_us&edition=fundamental","pubTime":"2026-01-20 12:02","pubTimestamp":1768881728,"startTime":"0","endTime":"0","summary":"FiberPro (KOSDAQ:368770) secured an inertial measurement unit (IMU) supply contract from Viavi Solutions, according to a Tuesday filing with the Korean Exchange.The deal is valued at 4.89 billion won.Shares of the precise motion measurement solutions provider jumped nearly 18% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2604139014","title":"BRIEF-Immuron Reports H1 Global Travelan Sales AUD$4.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2604139014","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604139014?lang=en_us&edition=fundamental","pubTime":"2026-01-19 22:25","pubTimestamp":1768832724,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Reports H1 Global Travelan Sales AUD$4.2 MlnJan 19 (Reuters) - Immuron Ltd IMC.AX:IMMURON REPORTS CONTINUED SALES GROWTHIMMURON LTD - H1 GLOBAL      TRAVELAN SALES AUD$4.2 MILLIONSource text: ID:nGNX6r0VRNFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUA8NBSQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMC.AU","BK7508"],"gpt_icon":0},{"id":"2604801571","title":"Immuron Limited Reports 5% Increase in Global H1 Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2604801571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604801571?lang=en_us&edition=fundamental","pubTime":"2026-01-19 19:00","pubTimestamp":1768820419,"startTime":"0","endTime":"0","summary":"Immuron Limited has reported continued sales growth for the first half  of the fiscal year. Global H1 sales reached AUD$4.2 million, an increase of 5% compared to the prior comparative period . Second quarter  global sales were AUD$2.2 million, up 11% on the previous quarter. In Australia, H1 sales totaled AUD$3.3 million, up 13% on pcp, with Q2 sales of AUD$1.7 million, an 11% increase on the prior quarter. The company also launched ProIBS in Australia during this period. In the USA, H1 sales were AUD$0.9 million, representing a 17% increase on pcp, with Q2 sales of AUD$0.4 million, up 8% from the previous quarter. Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales rose to AUD$42 thousand, an increase of 191% on the prior quarter. Immuron anticipates further growth in Canada with the upcoming launch of Travelan in Jean Coutu pharmacies in Quebec.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL6pKhxb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD","LU2095319765.USD","LU0314104364.USD","BK4585","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK7067","SG9999014005.SGD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK7508","NDAQ","IMC.AU","BK4112"],"gpt_icon":0},{"id":"2604180611","title":"Immuron Reports Continued Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2604180611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604180611?lang=en_us&edition=fundamental","pubTime":"2026-01-19 19:00","pubTimestamp":1768820400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUA8NBSQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2604901736","title":"Neuren Pharmaceuticals Confirms Compliance With ASX Listing Rules; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604901736","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604901736?lang=en_us&edition=fundamental","pubTime":"2026-01-19 11:37","pubTimestamp":1768793877,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  confirmed compliance with the listing rules of the Australian Securities Exchange , in particular, listing rule 3.1, after the company disclosed that its Nasdaq-listed partner forecasts Rett Syndrome drug global net sales of $700 million in 2028, according to a Monday Australian bourse filing.In response to an ASX query, the company said it complies with the rule, which mandates it to immediately disclose any information to the bourse that can reasonably be expected to affect its share price.The company's shares fell 4% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4543","BK7508","NEU.AU","BK7039","ASX.AU","BK4141","BK7096","ASX","BK4526"],"gpt_icon":0},{"id":"2604058999","title":"BRIEF-Polynovo Logs HY Group Sales Of A$68.2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2604058999","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604058999?lang=en_us&edition=fundamental","pubTime":"2026-01-19 09:21","pubTimestamp":1768785660,"startTime":"0","endTime":"0","summary":"BRIEF-Polynovo Logs HY Group Sales Of A$68.2MJan 19 (Reuters) - Polynovo Ltd PNV.AX:HY GROUP SALES OF A$68.2MFurther company coverage: PNV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nFWN3YH1YA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PNV.AU","BK7508","BK7126"],"gpt_icon":0},{"id":"2604034649","title":"BRIEF-Orthocell Posts Quarterly Revenue Of A$3.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2604034649","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604034649?lang=en_us&edition=fundamental","pubTime":"2026-01-19 09:10","pubTimestamp":1768785047,"startTime":"0","endTime":"0","summary":"BRIEF-Orthocell Posts Quarterly Revenue Of A$3.2 MillionJan 19 (Reuters) - Orthocell Ltd OCC.AX:QTRLY REVENUE OF A$3.2 MILLIONFurther company coverage: OCC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nFWN3YH1FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","OCC.AU"],"gpt_icon":0},{"id":"2604690894","title":"BUZZ-Australia's PolyNovo jumps on upbeat half-yearly sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2604690894","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604690894?lang=en_us&edition=fundamental","pubTime":"2026-01-19 08:24","pubTimestamp":1768782258,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's PolyNovo jumps on upbeat half-yearly sales ** Shares of Australia's PolyNovo PNV.AX rise as much as 6.2% to A$1.28, their highest level since December-end** Medtech co posts HY group sales of A$68.2 million , up from A$59.9 million a year earlier ** Stock up 1% YTD after a 39.7% fall in 2025  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nL6N3YK00Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7126","PNV.AU"],"gpt_icon":0},{"id":"2604908825","title":"BRIEF-Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L","url":"https://stock-news.laohu8.com/highlight/detail?id=2604908825","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604908825?lang=en_us&edition=fundamental","pubTime":"2026-01-19 08:04","pubTimestamp":1768781085,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-LJan 18 (Reuters) - Mesoblast Ltd MSB.AX:FDA ACKNOWLEDGES EFFECTS ON PAIN INTENSITY FAVOR REXLEMESTROCEL-L, CONFIRM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUA6Y1RZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK4139","BK7501","MSB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2604397003","title":"Mesoblast Advances Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain Following FDA Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2604397003","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604397003?lang=en_us&edition=fundamental","pubTime":"2026-01-19 08:01","pubTimestamp":1768780900,"startTime":"0","endTime":"0","summary":"Mesoblast Limited has announced feedback from the U.S. Food & Drug Administration  regarding its allogeneic cell therapy product, rexlemestrocel-L, for patients with chronic discogenic low back pain . The FDA acknowledged that effects on pain intensity favor rexlemestrocel-L based on data from the company's first randomized controlled Phase 3 trial , with a clinically meaningful reduction in pain intensity at 12 months supporting product efficacy. The FDA also indicated that results on opioid reduction from at least one adequate and well-controlled trial could be included in the Clinical Studies section of the product labeling. A second randomized controlled Phase 3 trial  is currently recruiting in the United States and is expected to complete enrollment in the coming months. Results from the first Phase 3 trial have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDLc5yjjf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B3QW5Z07.USD","BK7067","SG9999014021.USD","BK7501","BK7508","IE00BKPKM429.USD","BK4585","BK4588","MSB.AU","SG9999014013.SGD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","SG9999014039.USD","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD","BK4112","SG9999014005.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":97,"code":"91000000","status":"200"}]}}